Market Overview

Wedbush Raises PT On DexCom To $18 After In-Line 1Q Results


Wedbush Securities has published a research report on DexCom (NASDAQ: DXCM) after the company reported 1Q results that were in-line with analyst estimates.

In the report, Wedbush writes "DXCM reported Q1:11 product revenue of $13.1 million (-3% Q/Q; +94% Y/Y) which was in-line with consensus. Our Q1 product revenue estimate of $14.3 million was high because we failed to adequately account for seasonality common to the medical device industry. However, we remain comfortable with our full-year product revenue estimate of $70.6 million and have shifted our Q1 shortfall into Q4 given Q1 is seasonally the weakest quarter and Q4 the strongest. Management commented that they continue to see strong demand and had a full pipeline of patient referrals exiting the quarter."

Wedbush maintains its Outperform rating and has raised the price target from $17 to $18.

DexCom closed yesterday at $16.50.

Posted-In: dexcom Wedbush SecuritiesAnalyst Color Price Target Analyst Ratings


Related Articles (DXCM)

View Comments and Join the Discussion!

Latest Ratings

IBMWells FargoMaintains140.0
PNCWells FargoMaintains147.0
TWOUDA DavidsonMaintains17.0
IDYAOppenheimerInitiates Coverage On17.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

UPDATE: Jefferies Raises Price Target On DexCom Following Earnings (DXCM)

Duoyuan Global Water Inc. Announces Resignation of Four Directors (DGW)